Thyroid Cancer Drugs are consumed to prevent the secretion and release of thyroid hormones from the thyroid glands
For those
patients who do have thyroid disease and are candidates for surgery, radiation
treatment or transplant, access to an effective thyroid medication can make all
the difference in a positive outcome. There are other drugs in the works that
may treat thyroid cancer and several of these have already undergone phase III
clinical trials. One of these drugs is leupefin. Its manufacturer is Tosex
Pharmaceuticals and it has already been approved in Canada for use in the
treatment of lung cancer and renal cell carcinoma. In addition to treating
patients with this disease, leupefin is also reported to be effective in
treating breast cancer. It is being considered as an effective treatment for
both stage I and stage II cancers.
In September 2021, the Indian biopharmaceutical
company, BDR Pharma, launched Cabozantinib molecule, an inhibitor developed to
improve accessibility of thyroid
cancer drugs in the Asia Pacific region. Other new drugs being
developed include trilastin and gemcitabine. Trilastin is being studied for use
in the treatment of endometriosis, although its effect on tumors is less than
desirable. Gemcitabine is undergoing phase III clinical trials and is being
investigated for its ability to prevent and treat thyroid cancer. It has not
yet received approval from the FDA for these purposes. One more newly developed
drug, menthol, is also being tested for thyroid cancer treatment.
Since many of the existing drugs for treating hypothyroidism can have
side effects that can cause damage to the liver or kidneys, researchers are
constantly looking for other alternative ways of treating this condition.
Although these conventional methods have worked well for some people, they
still do not provide a full range of solutions. New alternatives to treating
this disease may soon become available. Thyroid cancer drugs are only one of
them.
Studies on how thyroid cancer drugs might affect one's
health are few and still inconclusive. Research is also limited in terms of
detecting toxicity at low doses. All of these factors combine to limit the
effectiveness of vandetanib and its contemporaries. There is some speculation
that future vandetanib may prove to be toxic, but until then, supply remains
too low to meet demand.
Comments
Post a Comment